How Noom Avoided PMF Collapse in the Wake of GLP-1s

Update: 2025-10-02

Description

Brent Zajaczkowski is the VP of Product Growth at Noom, one of the world’s largest preventive health platforms that is widely credited with pioneering a novel psychology-based approach to weight loss. Brent joined Noom in 2020 as a Senior PM, and has since been promoted multiple times. Prior to Noom, Brent spent 8+ years in product management and software engineering at TripAdvisor and Wyzant. He holds a Bachelor’s degree in Computer Engineering from Brown University.

Key Takeaways:

After being founded in 2008, Noom has become one of the largest online weight loss platforms in the world, and is widely credited with pioneering a novel, psychology-based approach to weight loss built on cognitive behavioral therapy.
Noom is famous for its “longboarding flow,” which asks users to answer dozens of questions to help personalize their weight loss plan and product experience. While this approach is unconventional, it works because Noom’s users have often tried many other ways to lose weight unsuccessfully, which means they need to be convinced that Noom will work where other solutions have failed.
Many of Noom’s most successful A/B tests have tapped into underlying user psychology to boost motivation. These include asking users to pay for a trial so they really commit to their weight loss program, and building a “re-onboarding” flow to encourage users who have fallen off the wagon to try again.
The proliferation of GLP-1 medications like Ozempic and Wegovy threatened Noom’s core business, but the company has adapted by investing in several PMF expansion bets, including offering GLP-1s through its own platform.
Recently, Noom built an AI companion called “Welli” that helps users navigate its increasingly complex service offering and receive a personalized experience, which has helped to increase user engagement and retention rates.

Brent Zajaczkowski: